These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 14676730

  • 1. [Calcium-phosphate metabolism and bone markers in two patients with Noonan's syndrome treated with growth hormone].
    Praticò G, Palano GM, Lo Presti D, Parisi G, Caruso-Nicoletti M.
    Minerva Pediatr; 2003 Dec; 55(6):593-8. PubMed ID: 14676730
    [Abstract] [Full Text] [Related]

  • 2. [Dynamics of bone biochemical markers in nephrotic children treated with prednisone and metabolites of vitamin D].
    Wojnar J, Roszkowska-Blaim M, Pańczyk-Tomaszewska M.
    Przegl Lek; 2007 Dec; 64(9):552-8. PubMed ID: 18510075
    [Abstract] [Full Text] [Related]

  • 3. An acute intake of phosphate increases parathyroid hormone secretion and inhibits bone formation in young women.
    Kärkkäinen M, Lamberg-Allardt C.
    J Bone Miner Res; 1996 Dec; 11(12):1905-12. PubMed ID: 8970892
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Long-term effects of growth hormone (GH) on bone mineral status and bone turnover markers in patients with isolated GH deficiency and multiple pituitary hormone deficiency.
    Gonc EN, Kandemir N.
    Clin Endocrinol (Oxf); 2007 May; 66(5):672-7. PubMed ID: 17381489
    [Abstract] [Full Text] [Related]

  • 7. Interactions of growth hormone and parathyroid hormone in renal phosphate, calcium, and calcitriol metabolism and bone remodeling in postmenopausal women.
    Lieberman SA, Holloway L, Marcus R, Hoffman AR.
    J Bone Miner Res; 1994 Nov; 9(11):1723-8. PubMed ID: 7863823
    [Abstract] [Full Text] [Related]

  • 8. Growth hormone treatment in children with Noonan's syndrome: four year results of a partly controlled trial.
    Noordam C, Van der Burgt I, Sengers RC, Delemarre-van de Waal HA, Otten BJ.
    Acta Paediatr; 2001 Aug; 90(8):889-94. PubMed ID: 11529537
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine.
    Karner I, Hrgović Z, Sijanović S, Buković D, Klobucar A, Usadel KH, Fassbender WJ.
    Eur J Med Res; 2005 Nov 16; 10(11):480-8. PubMed ID: 16354602
    [Abstract] [Full Text] [Related]

  • 19. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B, Kirmaz C, Aydin K, Kafesciler SO, Guclu F, Hekimsoy Z.
    Eur Cytokine Netw; 2007 Sep 16; 18(3):148-53. PubMed ID: 17823083
    [Abstract] [Full Text] [Related]

  • 20. [The influence of corticosteroid therapy on selected parameters of bone metabolism in children with nephrotic syndrome].
    Wojnar J, Pańczyk-Tomaszewska M, Szymanik-Grzelak H, Sieniawska M.
    Pol Merkur Lekarski; 1998 Oct 16; 5(28):195-8. PubMed ID: 10101441
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.